Journal List > J Korean Soc Transplant > v.25(1) > 1034357

J Korean Soc Transplant. 2011 Mar;25(1):38-42. Korean.
Published online March 31, 2011.
Copyright © 2011 The Korean Society for Transplantation
Case of ABO-Incompatible Living Donor Kidney Transplantation without Blood Products in a Jehovah's Witness
An Sook Choi, M.D., Seong Min Yu, M.D., Jin Ho Lee, M.D., Joon Suk Oh, M.D., Seong Min Kim, M.D., Yong Hun Sin, M.D., and Joong Kyung Kim, M.D.
Department of Internal Medicine, Bong Seng Memorial Hospital, Busan, Korea.

Corresponding author (Email: )
Received January 19, 2011; Accepted March 16, 2011.


ABO-incompatible kidney transplantations have been performed successfully in Korea without splenectomy using plasmapheresis, anti-CD20 monoclonal antibody infusions and other immunosuppressants. However, there is no report of a case of ABO-incompatible kidney transplantation in a Jehovah's Witness. Hence, we report our experience of successful ABO-incompatible kidney transplantation without blood products in a Jehovah's Witness. The recipient was treated with six sessions of plasmapheresis and he received intravenous rituximab before transplantation. Immunosuppressive regimen consisted of tacrolimus, mycophenolate mofetil and steroid. The replacement fluid for plasmapheresis was 5%% albumin solution instead of fresh frozen plasma. We measured the clotting factors before and after plasmapheresis and used cryoprecipitate to prevent bleeding.

Keywords: ABO-incompatible kidney transplantation; Clotting factors; Jehovah's Witness


Fig. 1
Clinical Course: fibrinogen progress on plasmapheresis during pretransplantation period. Abbreviation: PP, pretransplantation plasmapheresis.
Click for larger image

1. Kong JM, Lee DR, Jeong JH, Choi JH, Lee JO, Lee WR, et al. ABO blood group incompatible living donor kidney transplantation without splenectomy. J Korean Soc Transplant 2009;23:71–76.
2. Tydén G, Gunilla K, Helena G, John S, Torbjorn L, Ingella F. ABO-incompatible kidney transtrantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005;5:145–148.
3. Takahashi K, Saito K. Present status of ABO-incompatible kidney transplantation in Japan. Xenotransplantation 2006;13:118–122.
4. Wilpert J, Fischer KG, Pisarski P, Wiech T, Daskalakis M, Ziegler A, et al. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol Dial Transplant 2010;25:3778–3786.
5. Wilpert J, Geyer M, Teschner S, Schaefer T, Pisarski P, Schulz-Huotari C, et al. ABO-incompatible kidney transplantation-proposal of an intensified apheresis strategy for patients with high initial isoagglutinine titers. J Clin Apher 2007;22:314–322.
6. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004;4:1315–1322.
7. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006;6:2418–2428.
8. Tanabe K. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 2007;84 12 Suppl:S4–S7.
9. Tydén G, Donauer J, Wadström J, Kumlien G, Wilpert J, Nilsson T, et al. Implementation of a Protocol for ABO-incompatible kidney transplantation-a three-center experience with 60 consecutive transplantations. Transplantation 2007;83:1153–1155.
10. Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL. The new approach to assignment of ASFA categories-introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apher 2007;22:96–105.
11. Roback JD. In: Technical manual. 16th ed. Bethesda: American Association of Blood Bank; 2008. pp. 697-705.
12. Holt S, Donaldson H, Hazlehurst G, Varghese Z, Contreras M, Kingdon E, et al. Acute transplant rejection induced by blood transfusion reaction to the Kidd blood group system. Nephrol Dial Transplant 2004;19:2403–2406.
13. Wood L, Jacobs P. The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels. J Clin Apher 1986;3:124–128.
14. Karlsson M, Ternström L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion 2008;48:2152–2158.
15. Danés AF, Cuenca LG, Bueno SR, Mendarte Barrenechea L, Ronsano JB. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang 2008;94:221–226.
16. OShaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126:11–28.
17. Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009;23:177–188.
18. Brecher ME. In: Technical Manual. 15th ed. Batheda: American Association of Blood Bank; 2005. pp. 502-503.
19. Muramoto O. Recent developments in medical care of Jehovah's Witnesses. West J Med 1999;170:297–301.
20. Park KY, Park CH, Lee HJ, Lim CY, Kwon JH, Ahn TH, et al. Cardiac transplantation in a Jehovah's wittness: a case report. Korean J Thorac Cardiovasc Surg 1997;30:537–539.
21. Kaufman DB, Sutherland DE, Fryd DS, Ascher NL, Simmons RL, Najarian JS. A single-center experience of renal transplantation in thirteen Jehovah's Witnesses. Transplantation 1988;45:1045–1049.
22. Gohel MS, Bulbulia RA, Slim FJ, Poskitt KR, Whyman MR. How to approach major surgery where patients refuse blood transfusion (including Jehovah's Witnesses). Ann R Coll Surg Engl 2005;87:3–14.